Fate Therapeutics Inc (FATE) Implied Volatility Current

Tracking FATE implied volatility helps you identify when options premiums on Fate Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Fate Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when FATE IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Fate Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For FATE, tracking metrics like FATE IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on FATE signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.

The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where FATE implied volatility sits today versus where it has been. Our scanner ranks Fate Therapeutics Inc implied volatility against its historical range, surfaces extremes in FATE IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Fate Therapeutics Inc IV is rich or cheap — measure it, then act on it.